GI Dealmaking Is Heating Up — And the Terms Are Shifting

The GI Pipeline Gap Is Real — And Acquirers Know It

Gastroenterology has spent years as a secondary consideration for large pharma business development teams. Oncology, immunology, and neuroscience consumed the lion's share of deal activity and board-level attention. That's changing. Across our dataset, GI-focused transactions have been claiming a growing share of licensing and acquisition activity over the past several years, and the terms reflect a therapeutic area where competition for assets is intensifying faster than most founders realize.

The catalyst isn't mysterious. Several blockbuster GI franchises face patent cliffs within the next few years. Humira's biosimilar erosion is well underway. Entyvio (vedolizumab) — Takeda's crown jewel — faces biosimilar pressure in the near term. Stelara has already begun its transition. These aren't small revenue pools. Combined, they represent tens of billions in annual sales that incumbent holders and challengers alike need to defend or replace. The result is a buyer's market turning into a seller's market, at least for the right kind of asset.

What makes this moment unusual is the breadth of GI subdisciplines attracting capital. Inflammatory bowel disease (IBD) remains the anchor, but eosinophilic gastrointestinal diseases (EGIDs), motility disorders, gut-brain axis programs, and microbiome-based therapeutics are all pulling deals. The AbbVie/Cerevel transaction, while primarily neurological, underscored pharma's willingness to pay premiums for assets that touch the gut-brain connection. More directly, AstraZeneca's escalating investment in its EGID portfolio and Pfizer's continued build-out in IBD signal that the category is no longer a side bet.

IBD: Still the Center of Gravity, But the Bar Is Higher

IBD continues to dominate GI deal activity by a wide margin. The logic is straightforward: Crohn's disease and ulcerative colitis represent large, well-characterized patient populations with established regulatory pathways and clear commercial precedent. But the nature of what gets a deal done in IBD has shifted meaningfully.

Five years ago, a novel anti-TNF or integrin blocker with Phase 1 data could attract a partnership. Today, buyers want clinical differentiation — oral convenience, novel mechanisms, or demonstrable superiority against the current standard of care. The success of Velsipity (etrasimod), which Bristol Myers Squibb acquired through the $4.1B Turning Point deal, and the competitive dynamics around S1P receptor modulators have raised the floor for what constitutes a compelling IBD asset.

Across recent publicly disclosed transactions, we see a pattern: IBD deals with clinical-stage data in hand are commanding substantially higher upfront payments relative to earlier-stage deals in the same indication. Preclinical programs still get partnered, but the risk-sharing has shifted more heavily toward milestones. This is a market that's become sophisticated enough that buyers distinguish sharply between a differentiated mechanism with human proof-of-concept and a promising-looking mouse model.

One development worth watching: the growing interest in combination approaches. Several recent partnerships involve assets designed to work alongside existing biologics rather than replace them. This is a structural shift in how pharma thinks about IBD — not as a one-drug-wins market, but as a chronic condition requiring combination and sequencing strategies, much like oncology.

Beyond IBD: EGIDs and the Gut-Brain Axis Are Drawing Real Capital

The most interesting trend in GI dealmaking isn't happening in IBD. It's happening in the adjacent spaces where unmet need is acute and competition is thinner.

Eosinophilic esophagitis (EoE) has gone from orphan curiosity to competitive battlefield. Dupixent's approval in EoE was a watershed — it validated the commercial opportunity and proved that payers would cover biologic therapy in this setting. Since then, multiple pharma buyers have moved to secure pipeline assets targeting EoE and the broader EGID spectrum. The deal terms in this space tend to feature higher upfront-to-total-value ratios than comparable-stage IBD deals, reflecting the fact that buyers see a near-term commercial window they need to hit.

The gut-brain axis is earlier but generating meaningful deal activity. Programs targeting IBS, functional dyspepsia, and gastroparesis through CNS-GI crosstalk mechanisms are attracting interest from both traditional GI players and neuroscience-focused pharma. These deals tend to be structured as option-based collaborations with lower upfronts but significant milestone packages — buyers are paying for the right to see clinical data before committing to full economics.

Microbiome therapeutics remain in the picture but the sentiment has shifted. After years of hype and several clinical disappointments, the surviving companies in this space are commanding more modest valuations but finding serious partners for well-defined indications, particularly C. difficile recurrence and ulcerative colitis. Ferring's approval of Rebyota and the subsequent commercial trajectory have given buyers a reference point for what microbiome deals should look like economically — and it's more conservative than the 2019 vintage of microbiome term sheets would suggest.

Who's Buying — And What They're Willing to Pay For

The buyer landscape in GI has broadened considerably. Takeda, historically the dominant GI-focused acquirer, faces a strategic imperative to reload its pipeline as Entyvio revenues come under pressure. AbbVie, armed with Skyrizi and Rinvoq's GI label expansions, is buying selectively to fill specific gaps. Johnson & Johnson remains active following Tremfya's UC data. And newer entrants — AstraZeneca, Bristol Myers Squibb, and several mid-cap specialty pharma companies — have all signaled GI as a priority.

This broader buyer base matters for founders and investors. In our experience advising GI-focused companies, competitive tension in a process is the single biggest driver of upfront value. When three qualified buyers are at the table instead of one, the structure changes. Milestone-heavy, option-laden term sheets give way to cleaner economics: higher upfronts, fewer conditions on development milestones, and more favorable governance provisions.

What are buyers willing to pay up for? Three things stand out:

Oral delivery. GI buyers are paying premiums for oral small molecules and peptides over injectable biologics, even when the mechanism is similar. The commercial logic is sound — GI patients often cycle through multiple therapies, and oral convenience drives adoption.

Registrational-ready programs. Assets with clear Phase 2b or Phase 3 readiness are receiving meaningfully different treatment than earlier-stage programs. The gap between "interesting biology" and "clear path to NDA" has widened in GI, and the deal terms reflect it.

Platform extensibility. Programs that address one GI indication with a credible path to two or three others — particularly across both IBD and EGID — are attracting partnership structures that value the full portfolio, not just the lead asset.

These benchmarks are available in real-time on Solidus, our deal terms platform.

Implications

For GI biotech founders preparing for a partnership or sale process, the current environment is more favorable than it's been in years — but only if you understand what's driving buyer urgency. The patent cliff dynamic means pharma BD teams are under time pressure. They need assets that can reach the market within a defined window, typically before peak biosimilar erosion of their existing franchises. If your program timeline aligns with that urgency, you have negotiating power. If it doesn't, expect the conversation to center on option structures and milestone-heavy economics.

Investors evaluating GI-focused companies should pay attention to the deal structure trends in this space. The shift toward higher upfront payments for differentiated, later-stage assets suggests that the traditional biotech playbook of partnering early with a big GI player may be leaving value on the table. Companies that can fund themselves through Phase 2 proof-of-concept data are likely to capture significantly more value than those that partner at the preclinical or Phase 1 stage. The premium for human data in GI is substantial and growing.

For pharma BD executives, the message is simpler: move fast. The number of credentialed buyers in GI has expanded, and the best assets are running competitive processes. The days of being the only serious GI partner at the table are over for most indications. Proprietary deal flow still exists — particularly in earlier-stage gut-brain and microbiome programs — but for anything with IBD or EGID clinical data, expect a structured process and prepare to compete on terms, not just reputation. Companies going to market with oral assets in IBD or registrational-stage programs in EoE should expect robust interest and should plan their processes accordingly, running broad enough to create real competitive tension while moving quickly enough to match buyer timelines.